Kantarjian et al53 assessed the efficacy and protection of dasatinib, as in comparison with imatinib, for the primary-line cure of CML-CP. 5 hundred and nineteen individuals with recently diagnosed CML-CP have been randomly assigned to get dasatinib in a dose of a hundred mg at the time daily (259 patients) https://paxtonnbinz.xzblogs.com/70181527/the-single-best-strategy-to-use-for-fluoxetine